These tests are to see whether your CML is responding to treatment. Haematological response Your haematological response is based on whether your blood cells go back to normal levels. You usually have ...

According to the results, olverembatinib demonstrated high complete remission (CR) and complete molecular response (CMR) rates ... approved in China for the treatment of patients with CML in chronic ...

Response to treatment The aim of treatment is to put your CML into remission. Remission means there are no signs of CML in your blood. The doctors refer to remission as ‘response to treatment’. There ...

Major molecular response is defined as a reduction of bcr-abl transcript levels by 3 or more logs, compared with a standardized baseline, obtained from newly diagnosed and untreated CML patients.

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation ...

The number of colorectal cancer cases in people under 50 is rising worldwide, especially in high-income countries. Possible ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

The molecular basis of CML disease progression is not well understood, but probably results from additional genetic events in Bcr-Abl-transformed cells that may be independent of Bcr-Abl activity ...

Three of five patients with advanced colorectal cancer responded to leronlimab, including one complete response lasting five years, according to new data.

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine ...